Your shopping cart is currently empty

OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $215 | In Stock | In Stock | |
| 5 mg | $538 | In Stock | In Stock | |
| 10 mg | $778 | In Stock | In Stock | |
| 25 mg | $1,430 | In Stock | In Stock | |
| 50 mg | $2,450 | In Stock | In Stock | |
| 100 mg | $3,280 | - | In Stock | |
| 500 mg | $4,360 | 6-8weeks | 6-8weeks | |
| 1 mL x 10 mM (in DMSO) | $593 | In Stock | In Stock |
| Description | OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines. |
| Targets&IC50 | OGT:60 nM, OGT:3 μM (EC50) |
| In vitro | METHODS: HEK293T cells were treated with OSMI-4 (10 μM, 2 hours) and quantitative PCR was performed using primers for the OGT retained intron (intron 4) and spliced exon (exon 4). RESULTS The bar graph shows that OSMI-4 increases retained intron splicing. [1] METHODS: HEK293T cells were treated with OSMI-4 (20, 50 μM, 24 hours); HEK293T cells were treated with OSMI-4 (0.1, 1, 5, 5, 10, 20 μM, 2, 24, 48 hours); Western blot analysis of total O-GlcNAc was performed. RESULTS O-GlcNAc levels were reduced to a greater extent following OSMI-4 treatment; 24 hours of OSMI-4 treatment of HEK293T cells resulted in a dose-dependent decrease in O-GlcNAc levels, with effects seen with only 5 µM of compound treatment, and these effects could be observed in as little as 2 hours or 48 hours. [1] |
| Molecular Weight | 604.09 |
| Formula | C27H26ClN3O7S2 |
| Cas No. | 2260791-14-6 |
| Smiles | CCOC(=O)CN(Cc1cccs1)C(=O)[C@H](NS(=O)(=O)c1cc2ccc(=O)[nH]c2cc1Cl)c1ccccc1OC |
| Relative Density. | 1.414 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 252.5 mg/mL (417.98 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.